| The stock formed a confirmed Golden Cross on July 9.
It is currently navigating a technical consolidation phase after reaching recent highs, supported by strong institutional interest and strategic pipeline expansions. While high valuation and patent cliffs remain concerns, its Dividend King status and proactive M&A strategy sustain a bullish long-term trajectory.
Medium-Term (1-3 months) Summary:
The overall medium-term trajectory remains bullish as the stock trades well above the 50-day moving average.
Bullish: Robust institutional accumulation and strategic M&A momentum.
Bearish: Elevated valuation may limit immediate upside potential.
Signal rationale: The combination of sector rotation into healthcare and strong trend structure supports a 'buy on dips' approach to the rising 50-day moving average
Why watch?
1️⃣ Excellent financial health (Piotroski 7/9)
2️⃣ Beat earnings estimates in 3 of the last 4 quarters
3️⃣ Dividend Yield (TTM): 2.72%
| 
